Floatz logo

Vorinostat

Acute Lymphoblastic Leukemia

Explore 247 assets in Acute Lymphoblastic Leukemia →
Floatz Rating
B56/100
Confidence
Indicative
v0.2
Sponsor
Tanja Andrea Gruber
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05848687CT.gov
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
—Recruiting———
NCT03878524CT.gov
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
—Terminated———
NCT03117751CT.gov
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
—Active Not Recruiting———
NCT02553460CT.gov
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
—Active Not Recruiting———
NCT02419755CT.gov
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
—Terminated———
NCT02083250CT.gov
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
—Completed———
NCT01483690CT.gov
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
—Terminated———
NCT01312818CT.gov
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Acute Lymphoblastic Leukemia

AssetSponsorPhaseRating
Vorinostat (this asset)Tanja Andrea GruberP2/3B · 56
Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterP2/3BBB
Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineP4BBB
Thioguanine AnhydrousSt. Jude Children's Research HospitalP4BBB
Equine AtgInstituto Nacional de Cancer, BrazilP3BBB
PegaspargaseDana-Farber Cancer InstituteP4BB
Vincristine SulfateChildren's Oncology GroupP3BB
MethotrexatePrincess Maxima Center for Pediatric OncologyP4BB
CyclophosphamideSawa Ito, MDP4BB

+42 more in the Acute Lymphoblastic Leukemia cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Vorinostat in Acute Lymphoblastic Leukemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/vorinostat-acute-lymphoblastic-leukemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →